|
|
|
| Clinical effect of Alprostadil combined with Compound Biejia Ruangan Tablets and Entecavir in the treatment of HBeAg positive patients with decompensated liver cirrhosis |
| PANG Wenyan1 YANG Hongwei2 QI Ning3 ZHANG Guoshun4 |
1.Department of Integrated Traditional Chinese and Western Medicine, Tangshan Central Hospital, Hebei Province, Tangshan 063000, China;
2.Department of Nephrology, Tangshan People’s Hospital, Hebei Province, Tangshan 063000, China;
3.Department of Integrated Traditional Chinese and Western Medicine, North China University of Science and Technology Affiliated Hospital, Hebei Province, Tangshan 063000, China;
4.Department of Gastroenterology, North China University of Science and Technology Affiliated Hospital, Hebei Province, Tangshan 063000, China |
|
|
|
Abstract Objective To explore clinical effect of Alprostadil combined with Compound Biejia Ruangan Tablets and Entecavir in the treatment of hepatitis B e antigen (HBeAg) positive patients with decompensated liver cirrhosis. Methods One hundred and eight patients with HBeAg positive hepatitis B decompensated cirrhosis hospitalized in Tangshan Central Hospital from June 2018 to June 2019 were selected and divided into control group and case group according to the random number table method, with 54 cases in each group. Control group was given Compound Biejia Ruangan Tablets and Entecavir, and case group was given Alprostadil treatment based on control group. The course of treatment was four weeks. The liver and kidney function, serum inflammatory factors, virological indexes and clinical efficacy between two groups were observed before and after treatment. Results After treatment, the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) in two groups were lower than those before treatment, and the level of albumin (ALB) was higher than that before treatment, and the levels of ALT, AST and ALP in case group were lower than those in control group, and ALB level was higher than that in control group (P < 0.05). After treatment, the levels of laminin, hyaluronic acid, type Ⅲ procollagen and type Ⅳ collagen in two groups were lower than those before treatment, and those in case group were lower than those in control group (P < 0.05). After treatment, the portal vein diameter (Dpv) and splenic vein diameter (Dsv) of two groups were shorter than those before treatment, and the portal vein blood flow velocity (Vpv), portal vein blood flow (Qpv), splenic vein blood flow velocity (Vsv), and splenic vein blood flow (Qsv) were faster than those before treatment, and Dpv and Dsv of case group were shorter than those of control group, and Vpv, Qpv, Vsv and Qsv of case group were faster than those of control group (P < 0.05). After treatment, blood urea nitrogen (BUN), creatinine (Cr) and resistance index of two groups were lower than those before treatment, and renal blood flow (RBF) was faster than that before treatment, and BUN, Cr and resistance index of case group were lower than those of control group, and RBF of case group was faster than that of control group (P < 0.05). After treatment, the serum levels of interleukin-6, interleukin-8, tumor necrosis factor-α and C-reactive protein in two groups were lower than those before treatment, and those in case group were lower than those in control group (P < 0.05). After treatment, the levels of fibrinogen like protein 2 (FGL2), toll like receptor 4 (TLR-4), transforming growth factor beta 1 (TGF-β1) and aspartate aminotransferase platelet ratio index (APRI) in two groups were lower than those before treatment, and those in case group were lower than those in control group (P < 0.05). After treatment, the negative rate of HBV DNA, HBsAg and HBeAg in case group were higher than those in control group (P < 0.05). After treatment, total effective rate of case group was higher than that of control group (P < 0.05). Conclusion Alprostadil combined with Compound Biejia Ruangan Tablets and Entecavir can improve liver and kidney function, hepatic fibrosis and portal hemodynamics in patients with HBeAg positive decompensated liver cirrhosis, reduce HBV DNA load and inflammation, reduce FGL2, TLR-4, TGF-β1 and APRI levels, improve the body’s immune status.
|
|
|
|
|
|
[1] 王素辉，朱晓丽，王彩霞.异甘草酸镁治疗慢性乙型肝炎临床疗效观察[J].北方药学，2018，15（2）：49.
[2] 李宇，张平，郑渝梁，等.失代偿期乙型肝炎肝硬化并发慢加急性肝衰竭患者危险因素分析[J].肝脏，2019，24（6）：718-719.
[3] 陈廷宪，罗贤鑫，莫思柏.替比夫定与恩替卡韦治疗HBeAg阳性慢性乙型肝炎的对比研究[J].中国医药科学，2018，8（8）：46-48.
[4] 杨莎莎，周利.恩替卡韦联合百令胶囊治疗慢性乙型肝炎患者疗效初步研究[J].实用肝脏病杂志，2018，21（2）：204-207.
[5] 李宏谦.异甘草酸镁联合丹参对慢性乙型肝炎患者临床检验指标的影响[J].北方药学，2018，15（1）：185.
[6] 中华医学会肝病学分会，中华医学会感染病学分会.慢性乙型肝炎防治指南（2019年版）[J].肝脏，2019，24（12）：1335-1356.
[7] 葛均波，徐永健.内科学[M].8版.北京：人民卫生出版社，2014：419-423.
[8] 梁萍，郑荣琴.二维剪切波弹性成像评估慢性乙型肝炎肝纤维化临床应用指南[J].中华超声影像学杂志，2017， 26（11）：921-927.
[9] 侯慧，刘慧敏，周丽莉，等.核苷类抗病毒药物联合微生态制剂治疗HBV感染失代偿期肝硬化患者的临床效果[J].疑难病杂志，2019，18（4）：369-373.
[10] 郭熙清，钟庆.叶下珠胶囊联合多烯磷脂酰胆碱治疗慢性乙型肝炎的临床研究[J].现代药物与临床，2018，33（3）：578-581.
[11] 马筱妹.血液学相关指标对慢性乙型肝炎肝硬化的诊断价值[J].中国卫生检验杂志，2019，29（12）：1449-1452.
[12] 袁灵，曾白梅，林世德.慢性乙型肝炎患者核苷（酸）类似物治疗后相关肌损伤的发病机制及诊疗进展[J].临床肝胆病杂志，2019，35（3）：627-630.
[13] 李凡，罗薇，白纪红，等.慢性乙型肝炎肝硬化患者NLRP3及下游因子表达水平和意义[J].广东医学，2019，40（6）：782-786.
[14] 沈丽贤，王晓玲，李惠文.通络软坚胶囊联合恩替卡韦分散片治疗乙肝后肝纤维化的临床疗效及对相关指标的影响[J].河北医学，2020，26（7）：1220-1225.
[15] 安红杰，周东方.恩替卡韦联合复方鳖甲软肝片治疗乙型肝炎肝硬化患者疗效及转归研究[J].实用肝脏病杂志，2018，21（6）：903-906.
[16] 殷雪琴.复方鳖甲软肝片联合恩替卡韦治疗慢性乙型肝炎伴脾肿大患者疗效及相关影响因素分析[J].肝脏，2018，23（8）：699-701.
[17] 任方元，段俊.恩替卡韦联合复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化疗效观察[J].现代中西医结合杂志，2019，28（31）：3496-3499.
[18] 李莎莎，陈艳，曲建慧，等.恩替卡韦联合复方鳖甲软肝片治疗慢性乙型肝炎肝纤维化的临床效果评价[J].传染病信息，2019，32（2）：119-121，138.
[19] 郑婷婷，蒋珊珊，方钟燎，等.慢性乙型肝炎、肝硬化和肝衰竭患者肠道菌群变化研究[J].实用肝脏病杂志，2018，21（6）：899-902.
[20] 杨琴，马臻.复方鳖甲软肝片联合恩替卡韦治疗对慢性乙肝患者肝纤维化进程及免疫应答状态的影响[J].海南医学院学报，2018，24（5）：593-596.
[21] 刘均政.前列地尔辅助治疗对乙型肝炎肝硬化抗病毒疗效的影响[J].徐州医科大学学报，2019，39（3）：207-211.
[22] 阎双缓，张红霞，何立芳，等.前列地尔治疗乙型肝炎肝硬化并发肾损伤疗效观察[J].现代中西医结合杂志，2019，28（9）：932-935.
[23] 盘铮，李向永.前列地尔对乙肝肝硬化患者血清炎性因子以及肝功能的影响观察[J].北方药学，2019，16（2）：86-87.
[24] 孙海英，刘桂清.恩替卡韦治疗慢性乙型肝炎肝硬化失代偿期患者的疗效探讨[J].中国实用医药，2020，15（4）：100-101.
[25] 齐宁霞，韦丽娟.慢性乙型肝炎肝硬化患者血清铁蛋白（SF）水平变化及其临床价值[J].肝脏，2019，24（4）：471-472.
[26] 陆伟，刘丹萍，张占卿，等.APRI、GPR和FIB-4预测抗病毒诱导的乙型肝炎肝硬化肝脏病理学回归的性能评价[J].肝脏，2019，24（8）：875-882. |
|
|
|
